Immunoprophylaxis
Avaxim®
AVAXIM® is indicated for active immunization against infection caused by hepatitis A virus (HAV) in persons 12 years of age and older. AVAXIM® can be used for primary immunization or as a booster following primary immunization with AVAXIM® or other similar hepatitis A vaccines.
IMOVAX®
IMOVAX® Rabies is indicated for the active immunization of individuals of all age groups to prevent disease caused by the rabies virus. It is indicated for both pre-exposure prophylaxis and post-exposure prophylaxis. IMOVAX® Rabies should be used in accordance with official recommendations.
MenQuadfi®
MenQuadfi® is indicated for active immunization for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W and Y in individuals 12 months of age and older. MenQuadfi does not prevent N. meningitidis serogroup B disease.
Consult the respective product monographs (listed above) for important information on indications and clinical use, contraindications, warnings, precautions, adverse reactions, drug interactions, dosing, and administration. These product monographs are also available through our medical department at 1-888-852-6887.
1. Beyfortus® Product Monograph. Sanofi-aventis Canada Inc. April 19, 2023.
2. Fluzone® High-Dose Quadrivalent. Product Monograph. Sanofi-aventis Canada Inc. April 19, 2022.
3. SupemtekTM. Product Monograph. Sanofi-aventis Canada Inc. April 28, 2022.
